Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease
Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.
  • Gastric/Esophageal Cancer
  • Recorded Webcast
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation